EyePoint Pharmaceuticals
EYPT
$19.74
Share price
-1.00%
Change (1 day)
191.15%
Change (1 year)
Categories
P/S ratio for EyePoint Pharmaceuticals (EYPT)
P/S ratio as of May 2024 (TTM): 22.6
According to EyePoint Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 22.5685. At the end of 2023 the company had a P/S ratio of 24.5.
P/S ratio history for EyePoint Pharmaceuticals from 2005 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 24.5 | 751.28% |
| 2022 | 2.88 | -74.35% |
| 2021 | 11.2 | 288.55% |
| 2020 | 2.89 | -65.29% |
| 2019 | 8.33 | -90.41% |
| 2018 | 86.9 | 363.72% |
| 2017 | 18.7 | 120.42% |
| 2016 | 8.50 | -89.71% |
| 2015 | 82.6 | 1820.76% |
| 2014 | 4.30 | -91.29% |
| 2013 | 49.4 | 316.17% |
| 2012 | 11.9 | 227.12% |
| 2011 | 3.63 | -34.38% |
| 2010 | 5.53 | 10.37% |
| 2009 | 5.01 | 163.24% |
| 2008 | 1.90 | 147.64% |
| 2007 | 0.7685 | 103.1% |
| 2006 | 0.3784 | -99.75% |
| 2005 | 154 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Nymox Pharmaceutical NYMX | N/A | N/A | Bahamas |
 NRC Health
NRC | 5.62 | -75.10% | 🇺🇸 USA |